Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma

dc.contributor.author	Kling, Simon
dc.date.accessioned	2019-03-20T15:20:52Z
dc.date.available	2019-03-20T15:20:52Z
dc.date.issued	2017
dc.identifier.issn	1949-2553
dc.identifier.uri	http://hdl.handle.net/10900/87183
dc.language.iso	en	en
dc.publisher	Impact Journals Llc	de_DE
dc.relation.uri	http://dx.doi.org/10.18632/oncotarget.22334
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.subject.ddc	570	de_DE
dc.title	Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190131163842_00076
utue.publikation.seiten	107096-107108	de_DE
utue.personen.roh	Kissel, Maria
utue.personen.roh	Berndt, Sandra
utue.personen.roh	Fiebig, Lukas
utue.personen.roh	Kling, Simon
utue.personen.roh	Ji, Qunsheng
utue.personen.roh	Gu, Qingyang
utue.personen.roh	Lang, Tina
utue.personen.roh	Hafner, Frank-Thorsten
utue.personen.roh	Teufel, Michael
utue.personen.roh	Zopf, Dieter
dcterms.isPartOf.ZSTitelID	Oncotarget	de_DE
dcterms.isPartOf.ZS-Issue	63	de_DE
dcterms.isPartOf.ZS-Volume	8	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät